MedTrace Logo

FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation

NCT03584711 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2025-06-29

No results posted yet for this study

Summary

Single-arm, multi-centre phase II study The primary objective is to evaluate the time to failure of the strategy.

Conditions

Interventions

COMBINATION_PRODUCT

FOLFOX + panitumumab

FOLFOX + panitumumab according to a "stop and go" strategy with a reintroduction loop after progression on fluoropyrimidine as maintenance treatment

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Federation Francophone de Cancerologie Digestive

    lead OTHER

Principal Investigators

  • Jean-Baptiste Bachet, Pr · Federation Francophone de Cancerologie Digestive

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-26
Primary Completion
2025-03-30
Completion
2025-03-30

Countries

  • France
  • Martinique

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03584711 on ClinicalTrials.gov